Avacta
£12.5m raise completed, runway extended into Q227Scancell
Atlantic crossing transforms outlookAvacta
H126: pre|CISION pipeline progress prompts fundraiseAvacta
Encouraging first data from AVA6103 Phase Ia studyHUTCHMED
First ATTC deal: GSK $110m upfront for KRAS/EGFROxford BioDynamics
£9m raise gives management time to enact strategyHUTCHMED
SAFFRON data positions savo combo competitivelyHUTCHMED
H126: China recovery and Fruzaqla drive sales growthScancell
Strategic transactions to unlock longer-term valueAvacta
Tumour-activated drug delivery demonstrated